Document is current
Any future updates will be listed below
-
Authors
Lamprea-Montealegre, Julio A.
Joshi, Priya
Shapiro, Abigail S.
Madden, Erin
Navarra, Krista
Potok, O. Alison
Gregg, L. Parker
Podchiyska, Tanya
Robinson, Amy
Goldstein, Mary K.
Peralta, Carmen A.
Jassal, Simerjot K.
Navaneethan, Sankar D.
Rifkin, Dena. E.
Wang, Virginia
Shlipak, Michael G.
Estrella, Michelle M. https://orcid.org/0000-0002-8902-9576
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (SDR 20-387)
- License Information
-
More Information
Article History
Received: 20 December 2021
Accepted: 14 September 2022
First Online: 12 October 2022
Declarations
:
: C<sup>3</sup> research protocol was approved by UCSF IRB number 19–29496 on July 6, 2020. An amendment to this protocol was approved by UCSF IRB number 20–31328 on September 14, 2021. The protocol was also approved by Baylor College of Medicine IRB number H48413 and reviewed and approved the R&D committee, MEDVAMC, Houston, Texas.The UCSF IRB number waived informed consent as the research is no more than minimal risk to subjects, could not practically be done without the waiver, will not adversely affect rights and welfare of subjects, and will provide subjects with additional pertinent information after participation, whenever it is appropriate. The waiver of informed consent applies to all subjects.
: Not applicable.
: JLM, MGS, and MME have a collaborative agreement with Bayer, Inc. MGS and MME have received an honorarium from Boehringer-Ingelheim, Inc. and AztraZeneca CP is Chief Medical Officer at Cricket Health, Inc. SDN reports receiving personal fees from Bayer, Boehringer-Ingelheim, REATA, Tricida, and Vifor and research grants from Keryx, outside the submitted work.
